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Dear Editor, 
 
In a recent European survey, most transplant physicians declared systematically screening for asymptomatic 
bacteriuria (ASB) in kidney transplant recipients attending the outpatient clinic for post-transplant surveillance, 
and often administering antibiotics when ASB was found [1]. This screen-and-treat strategy relies on the 
premise that eradication of ASB can improve patient outcomes after kidney transplantation, by decreasing the 
risk of graft pyelonephritis. 
 
This month, the Infectious Diseases Society of America (IDSA) released an update to its guidelines for ASB [2]. 
Surprisingly, a strong recommendation has been made against the screen-and-treat strategy for ASB among 
kidney transplant recipients, based on high quality evidence (i.e., the highest level of quality possible). These 
conclusions are in contrast with those from our recent Cochrane review [3], in which we found only low quality 
evidence, and concluded that antibiotics had uncertain effects on preventing pyelonephritis and other urinary 
tract infections among kidney transplant recipients with ASB. So, why the distinctly different interpretations of 
the evidence, despite similar research questions?  
 
Interestingly, both conclusions followed similar research processes: systematic reviews of the evidence, and 
application of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to 
rate quality of evidence. There was no relevant new primary research study published between the Cochrane 
review and the IDSA guidelines. Apart from retrospective observational studies (which were, by nature, 
inherently biased for questions of intervention, and so not very helpful to answer the research question), we 
identified only two interventional studies [4, 5]. One of them was a small quasi-randomized study in which the 
incidence of pyelonephritis was not reported, making impossible to determine the effect of antibiotics on the 
risk of pyelonephritis in kidney transplant recipients with ASB [5]. 
 
Consequently, both the Cochrane review and the guidelines were left with only one intervention study to 
determine the effect of antibiotics on the risk of pyelonephritis among kidney transplant recipients with ASB 
[4]. This study was randomized, but there were limitations that made us downgrade the evidence quality from 
high to low. First, the sample size was based on an overoptimistic expectation of treatment effect (i.e., an 
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incidence of pyelonephritis reduced from 23% in the untreated arm to 3% in the antibiotics arm). Second, there 
were significant problems in the way the intended strategies were applied, as the screen-and-treat strategy 
was correctly applied in only half of participants from the antibiotic arm. Third, there were incomplete 
outcome data, with only just over half of study participants completing the planned follow-up. Fourth, 
pyelonephritis occurred in only nine patients in total, so the effect estimates were imprecise for the effect of 
antibiotics on the risk of pyelonephritis. This is illustrated by the wide confidence interval (CI) surrounding the 
risk ratio (RR 0.89, 95%CI 0.25-3.14), encompassing both an important decrease (by 75%) and increase (by 
214%) in the risk of pyelonephritis.  
 
Therefore, we question the IDSA’s conclusion there is high quality evidence, and the basis of the strong 
recommendation that was made against a screen-and-treat strategy for ASB in this population.  
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